| scholarly article | Q13442814 |
| P2093 | author name string | Peter B Berger | |
| Brent A Williams | |||
| Michael A Evans | |||
| Ashley M Honushefsky | |||
| P2860 | cites work | Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation | Q43427672 |
| Pathways to poor anticoagulation control | Q44607030 | ||
| Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials | Q45139213 | ||
| Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. | Q46026454 | ||
| Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control | Q46210612 | ||
| Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study | Q48172796 | ||
| Quality of Anticoagulation With Vitamin K Antagonists. | Q49071154 | ||
| A method to determine the optimal intensity of oral anticoagulant therapy. | Q51058560 | ||
| National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. | Q51163854 | ||
| Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. | Q51243653 | ||
| SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. | Q53089449 | ||
| General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. | Q53118400 | ||
| Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. | Q53146463 | ||
| Non-valvular atrial fibrillation: potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants | Q56969459 | ||
| New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs | Q59541701 | ||
| Atrial fibrillation | Q82941599 | ||
| Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation | Q22305336 | ||
| Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions | Q26764853 | ||
| 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society | Q29614693 | ||
| Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression | Q33891646 | ||
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | Q34134664 | ||
| Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study | Q34186228 | ||
| Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines | Q34336306 | ||
| The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study. | Q34481273 | ||
| Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? | Q35026442 | ||
| Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. | Q35903784 | ||
| Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice | Q36168742 | ||
| Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States | Q36808315 | ||
| Completion of guideline-recommended initial evaluation of atrial fibrillation | Q36838571 | ||
| Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke | Q37497566 | ||
| Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review | Q37661890 | ||
| Underuse of oral anticoagulants in atrial fibrillation: a systematic review | Q37770666 | ||
| Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. | Q38079101 | ||
| Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke | Q38116157 | ||
| Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. | Q38174309 | ||
| Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice. | Q38185977 | ||
| Individualized approaches to thromboprophylaxis in atrial fibrillation | Q38752254 | ||
| How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring | Q38791898 | ||
| NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank | Q38864297 | ||
| Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population | Q39389839 | ||
| Inappropriate use of oral anticoagulants for patients with atrial fibrillation | Q40203889 | ||
| Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study). | Q40340142 | ||
| Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry | Q40816883 | ||
| Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea | Q41048561 | ||
| Improving Anticoagulation Measurement Novel Warfarin Composite Measure | Q41287918 | ||
| Comparison of the Abilities of Summary Measures of International Normalized Ratio Control to Predict Clinically Relevant Bleeding | Q41432301 | ||
| Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). | Q42960824 | ||
| P433 | issue | 10 | |
| P921 | main subject | (RS)-warfarin | Q407431 |
| Atrial Fibrillation | Q815819 | ||
| P577 | publication date | 2017-10-12 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation | |
| P478 | volume | 6 |
Search more.